Alan V. Boddy - Publications, H-index & Citations

Alan V. Boddy

mayo clinic

48H指数

273论文数

7.8K被引数

收录论文 87

发表时间

ALLG APML5: bioavailability and safety of oral arsenic trioxide assessed during consolidation therapy for APL ALLG APML5：三氧化二砷口服生物利用度及安全性评估，评估时间在APL巩固治疗期间

BLOOD ADVANCES

IF7.1

2025-01-28

OAAI

Iland, Harry J.; Reynolds, John; Boddy, Alan, V; Schultz, Hayley B.; Khoo, Liane; Fleming, Shaun; Lane, Steven W.; Weber, Nicholas; Gasiorowski, Robin; Armytage, Tasman; Harrup, Rosemary; Watson, Anne-Marie; Tan, Peter; Filshie, Robin; Kwok, Fiona; Stevenson, William; Yuen, Sam; Ng, Ashley P.; Rowley, Leesa; Marlton, Paula; Wei, Andrew H.

Physiologically-based pharmacokinetic model predictions of inter-ethnic differences in imatinib pharmacokinetics and dosing regimens

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

IF3

2021-10-15

OAAI

Adiwidjaja, Jeffry; Gross, Annette S.; Boddy, Alan, V; McLachlan, Andrew J.

Is there scope for better individualisation of anthracycline cancer chemotherapy?

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

IF3

2020-11-30

OAAI

Sallustio, Benedetta C.; Boddy, Alan V.

Physiologically-Based Pharmacokinetic Predictions of the Effect of Curcumin on Metabolism of Imatinib and Bosutinib:In VitroandIn VivoDisconnect

PHARMACEUTICAL RESEARCH

IF4.3

2020-06-11

PREAI

Adiwidjaja, Jeffry; Boddy, Alan, V; McLachlan, Andrew J.

Potential for pharmacokinetic interactions between Schisandra sphenanthera and bosutinib, but not imatinib: in vitro metabolism study combined with a physiologically-based pharmacokinetic modelling approach

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

IF3

2020-05-13

OAAI

Adiwidjaja, Jeffry; Boddy, Alan V.; McLachlan, Andrew J.

Wnt receptor gene FZD1 was associated with schizophrenia in genome-wide SNP analysis of the Australian Schizophrenia Research Bank cohort 在澳大利亚精神分裂症研究银行队列的全基因组SNP分析中，Wnt受体基因FZD1与精神分裂症相关

AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY

IF3.7

2019-11-16

PREAI

Liu, Xiaoman; Low, Siew-Kee; Atkins, Joshua R.; Wu, Jing Qin; Reay, William R.; Cairns, Heath M.; Green, Melissa J.; Schall, Ulrich; Jablensky, Assen; Mowry, Bryan; Michie, Patricia T.; Catts, Stan V.; Henskens, Frans; Pantelis, Christos; Loughland, Carmel; Boddy, Alan V.; Tooney, Paul A.; Scott, Rodney J.; Carr, Vaughan J.; Cairns, Murray J.

Population pharmacokinetics of carboplatin, etoposide and melphalan in children: a re-evaluation of paediatric dosing formulas for carboplatin in patients with normal or mild impairment of renal function

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

IF3

2018-11-04

OAAI

Duong, J. K.; Veal, G. J.; Nath, C. E.; Shaw, P. J.; Errington, J.; Ladenstein, R.; Boddy, A. V.

A Strategy to Refine the Phenotyping Approach and Its Implementation to Predict Drug Clearance: A Physiologically Based Pharmacokinetic Simulation Study

CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY

IF3

2018-10-24

OAAI

Adiwidjaja, Jeffry; Boddy, Alan, V; McLachlan, Andrew J.

Investigating the potential impact of dose-banding for systemic anticancer therapy (SACT) in the pediatric setting based on pharmacokinetic evidence

CANCER RESEARCH

IF16.6

2018-07-01

PREAI

White-Koning, Melanie; Osborne, Caroline; Paci, Angelo; Boddy, Alan V.; Chatelut, Etienne; Veal, Gareth J.

Investigating the potential impact of dose banding for systemic anti-cancer therapy in the paediatric setting based on pharmacokinetic evidence

EUROPEAN JOURNAL OF CANCER

IF7.1

2018-03-01

OAAI

White-Koning, Melanie; Osborne, Caroline; Paci, Angelo; Boddy, Alan V.; Chatelut, Etienne; Veal, Gareth J.

Curcumin as a clinically-promising anti-cancer agent: pharmacokinetics and drug interactions

EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY

IF3.4

2017-08-10

140

PREAI

Adiwidjaja, Jeffry; McLachlan, Andrew J.; Boddy, Alan V.

A population pharmacokinetic model of AT9283 in adults and children to predict the maximum tolerated dose in children with leukaemia

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

IF3

2017-03-05

OAAI

Duong, Janna K.; Griffin, Melanie J.; Hargrave, Darren; Vormoor, Josef; Edwards, David; Boddy, Alan V.

Pharmacokinetics of dabrafenib in a patient with metastatic melanoma undergoing haemodialysis dabrafenib在接受血液透析的转移性黑色素瘤患者中的药代动力学

PIGMENT CELL & MELANOMA RESEARCH

IF2.6

2017-01-29

PREAI

Park, John J.; Boddy, Alan V.; Liu, Xiaoman; Harris, David; Lee, Vincent; Kefford, Richard F.; Carlino, Matteo S.

Pharmacogenetic association of MBL2 and CD95 polymorphisms with grade 3 infection following adjuvant therapy for breast cancer with doxorubicin and cyclophosphamide

EUROPEAN JOURNAL OF CANCER

IF7.1

2017-01-01

OAAI

Jamieson, David; Sunter, Nicola; Muro, Sara; Pouche, Lucie; Cresti, Nicola; Lee, Johanne; Sludden, Julieann; Griffin, Melanie J.; Allan, James M.; Verrill, Mark W.; Boddy, Alan V.

A phase I pharmacokinetic and pharmacodynamic study of the oral mitogen-activated protein kinase kinase (MEK) inhibitor, WX-554, in patients with advanced solid tumours

EUROPEAN JOURNAL OF CANCER

IF7.1

2016-11-01

OAAI

Jamieson, David; Griffin, Melanie J.; Sludden, Julieann; Drew, Yvette; Cresti, Nicola; Swales, Karen; Merriman, Mark; Allen, Rodger; Bevan, Paul; Buerkle, Markus; Mala, Carola; Coyle, Vicky; Rodgers, Lisa; Dean, Emma; Greystoke, Alastair; Banerji, Udai; Wilson, Richard H.; Evans, T. R. Jeffery; Anthoney, Alan; Ranson, Malcolm; Boddy, Alan V.; Plummer, Ruth

Plasma Retinol Kinetics and β-Carotene Bioefficacy Are Quantified by Model-Based Compartmental Analysis in Healthy Young Adults with Low Vitamin A Stores

JOURNAL OF NUTRITION

IF3.8

2016-10-01

OAAI

Green, Michael H.; Ford, Jennifer Lynn; Oxley, Anthony; Green, Joanne Balmer; Park, Hyunjin; Berry, Philip; Boddy, Alan V.; Lietz, Georg

A Retinol Isotope Dilution Equation Predicts Both Group and Individual Total Body Vitamin A Stores in Adults Based on Data from an Early Postdosing Blood Sample

JOURNAL OF NUTRITION

IF3.8

2016-10-01

OAAI

Green, Michael H.; Ford, Jennifer Lynn; Green, Joanne Balmer; Berry, Philip; Boddy, Alan V.; Oxley, Anthony; Lietz, Georg

Imagestream detection and characterisation of circulating tumour cells - A liquid biopsy for hepatocellular carcinoma?

JOURNAL OF HEPATOLOGY

IF33

2016-08-01

OAAI

Ogle, Laura F.; Orr, James G.; Willoughby, Catherine E.; Hutton, Claire; McPherson, Stuart; Plummer, Ruth; Boddy, Alan V.; Curtin, Nicola J.; Jamieson, David; Reeves, Helen L.

The implications of genetic variation for the pharmacokinetics and pharmacodynamics of aromatase inhibitors

EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY

IF3.4

2016-06-16

PREAI

Liu, Xiaoman; Low, Siew-Kee; Boddy, Alan V.

Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer (vol 114, pg 723, 2016)

BRITISH JOURNAL OF CANCER

IF6.8

2016-05-26

OAAI

Drew, Yvette; Ledermann, Jonathan; Hall, Geoff; Rea, Daniel; Glasspool, Ros; Highley, Martin; Jayson, Gordon; Sludden, Julieann; Murray, James; Jamieson, David; Halford, Sarah; Acton, Gary; Backholer, Zoe; Mangano, Raffaella; Boddy, Alan; Curtin, Nicola; Plummer, Ruth

研究方向